IP Library › Granted Patent US 12,358,977
Granted Patent B2
US 12,358,977 · App. 16/507,126 · Granted Jul 15, 2025

Treatment of acute exacerbations of chronic obstructive pulmonary disease by antagonism of the IL-20R

Inventors: Philippe Gosset (Lille, FR); Muriel Pichavant (Lille, FR); Magdiel Perez-Cruz (Lille, FR); Bachirou Kone (Lille, FR)
Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); INSTITUT PASTEUR DE LILLE; UNIVERSITE DE LILLE 1 SCIENCES ET TECHNOLOGIES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2
C07K16/244C07K16/2866C07K16/2887A61K39/00A61K2039/505C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,358,977
App. No.
16/507,126
Granted
Jul 15, 2025
Kind
B2
Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of acute exacerbation of chronic obstructive pulmonary disease. In particular, the present invention relates to a method of treating acme exacerbation of chronic obstructive pulmonary disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of IL-20 cytokines.

Claims (6)

1. A method of treating acute exacerbation of chronic obstructive pulmonary disease (COPD) in a subject having a defective response to a respiratory infection caused by bacteria, comprising administering to the subject a therapeutically effective amount of an antibody against IL-20 receptor subunit beta; wherein the defective response to the infection caused by bacteria is decreased production of IL-17 and IL-22 by blood mononuclear cells (MNC), compared to healthy control subjects, upon exposure to the bacteria; and wherein the production of IL-17 and IL-22 by the MNC is measured in an ELISA assay after the MNC from the subject are stimulated with S. pneumoniae or PHA in vitro.

2. The method of claim 1 , wherein the bacteria are Streptococcus pneumoniae, Haemophilus influenzae , and/or Moraxella catarrhalis.

3. The method of claim 1 , wherein the antibody against IL-20 receptor subunit beta is the monoclonal antibody 20RNTC.

4. The method of claim 1 , wherein the subject is a frequent exacerbator.

5. The method of claim 4 , wherein the subject is undergoing treatment for COPD and experiences at least 2 acute exacerbations during a 12-month period.

6. The method of claim 5 , wherein the subject experiences 3 or more acute exacerbations during a 12-month period.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Jul 8, 2024
From: UNIVERSITÉ DE DROIT ET DE LA SANTÉ DE LILLE 2; UNIVERSITÉ DE LILLE 1 SCIENCES ET TECHNOLOGIES; UNIVERSITÉ DE LILLE
To: UNIVERSITÉ DE LILLE
Reel/Frame 067922/0389 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2019
From: GOSSET, PHILIPPE; PICHAVANT, MURIEL; PEREZ-CRUS, MAGDIEL; KONE, BACHIROU
To: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); INSTITUT PASTEUR DE LILLE; UNIVERSITE DE LILLE 1 SCIENCES ET TECHNOLOGIES; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2
Reel/Frame 049707/0656 →
Priority Claims (1)
EP 14306868 · Nov 24, 2014 · regional
Continuity (2)
Continuation 15525799
Related Publication 20190330330A1 · Oct 31, 2019
References Cited (8)
US 20050142108A1 · Grunig · 2005 [cited by examiner]
Goel et al. Plasticity within the Antigen-Combining Site May Manifest as Molecular Mimicry in the Humoral Immune Response. J. Immunol. 2004; 173:7358-7367. [cited by examiner]
Sapey et al. COPD exacerbations ? 2: Aetiology. Thorax. Mar. 2006; 61(3): 250-258. [cited by examiner]
Myles et al. Signaling via the IL-20 receptor inhibits cutaneous production of IL-1β and IL-17A to promote infection with methicillin-resistant [cited by examiner]
Evensen, A.E. Management of COPD Exacerbations. Am Fam Physician. Mar. 1, 2010;81(5):607-13. [cited by examiner]
Liu et al. Emerging Biological Functions of IL-17A: A New Target in Chronic Obstructive Pulmonary Disease? Front Pharmacol. Jul. 2, 2021:12:695957. [cited by examiner]
Ding et al. IL-17 Aggravates Pseudomonas aeruginosa Airway Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Front Immunol. Jan. 13, 2022:12:811803. [cited by examiner]
Chen et al. Alterations of plasma inflammatory biomarkers in the healthy and chronic obstructive pulmonary disease patients with or without acute exacerbation. J Proteomics. Jun. 6, 2012;75(10): 2835-43. [cited by examiner]